#1 Clinical Trials Search in Europe

Hydroxypropylbetadex

This article discusses recent clinical trials investigating the use of Hydroxypropylbetadex, also known as Trappsol® Cyclo™, in treating two different neurological conditions: Early Alzheimer’s Disease and Niemann-Pick Disease Type C1. These studies aim to evaluate the safety, tolerability, and potential efficacy of this drug in addressing the symptoms and progression of these challenging disorders.

Table of Contents

What is Hydroxypropylbetadex?

Hydroxypropylbetadex, also known as hydroxypropyl-beta-cyclodextrin or HPβCD, is a chemical compound being studied for its potential therapeutic effects in various neurological disorders[1][2]. It is a modified form of cyclodextrin, a type of sugar molecule with a unique ring structure that can interact with other molecules.

Potential Uses

Current research is exploring the use of hydroxypropylbetadex in treating two main conditions:

  1. Alzheimer’s Disease: A progressive brain disorder that affects memory, thinking, and behavior[1].
  2. Niemann-Pick Disease Type C1 (NPC1): A rare genetic disorder that affects the body’s ability to transport cholesterol and other fatty substances within cells[2].

Alzheimer’s Disease Study

A clinical trial is underway to evaluate the safety and potential effectiveness of hydroxypropylbetadex in patients with early Alzheimer’s disease[1]. Here are some key points about the study:

  • The drug is being tested under the brand name Trappsol® Cyclo™.
  • It is administered through monthly infusions.
  • The study aims to assess safety, tolerability, and potential efficacy over 24 weeks.
  • Participants are adults aged 50 to 80 with mild cognitive impairment due to Alzheimer’s disease.

The researchers are particularly interested in monitoring for any side effects and measuring how the drug moves through the body (pharmacokinetics)[1].

Niemann-Pick Disease Type C1 Study

Another clinical trial is investigating hydroxypropylbetadex for the treatment of Niemann-Pick Disease Type C1[2]. This study has the following characteristics:

  • It’s a Phase 3 trial, which is typically the final stage before seeking approval for widespread use.
  • The drug is being tested in combination with standard care treatments.
  • The study will last for 96 weeks (about 2 years).
  • Participants must be at least 3 years old and have a confirmed diagnosis of NPC1.

The main goal is to see if the drug can improve various aspects of the disease, including movement, fine motor skills, speech, swallowing, and cognition[2].

Administration and Dosage

In both studies, hydroxypropylbetadex is administered as an intravenous infusion, which means it’s delivered directly into the bloodstream through a vein[1][2]. The dosage varies depending on the condition being treated:

  • For Alzheimer’s disease: Up to 1000 mg/kg per infusion, with a maximum total dose of 7000 mg/kg over 24 weeks[1].
  • For Niemann-Pick Disease Type C1: 2000 mg/kg per infusion, with treatments given over 96 weeks[2].

Safety and Side Effects

As these are ongoing clinical trials, the full safety profile of hydroxypropylbetadex is still being determined. However, researchers are closely monitoring for potential side effects, including[1]:

  • Infusion reactions
  • Changes in brain imaging (ARIA-H or ARIA-E)
  • Hearing loss
  • Changes in vital signs, physical examinations, and laboratory values

It’s important to note that potential risks and benefits should always be discussed with a healthcare provider.

Conclusion

Hydroxypropylbetadex represents a promising area of research in the treatment of Alzheimer’s disease and Niemann-Pick Disease Type C1. While the results of these clinical trials are not yet known, they may provide valuable insights into new treatment options for these challenging neurological conditions. As research progresses, we may learn more about the effectiveness and safety of this potential therapy.

Aspect Alzheimer’s Disease Trial Niemann-Pick Disease Type C1 Trial
Study Type Randomized, Placebo-controlled, Double-blind Phase 3, Double-blind, Randomized, Placebo-controlled
Duration 24 weeks 96 weeks
Primary Objectives Assess safety, tolerability, and potential efficacy Evaluate effectiveness using NPC Severity Scales
Dosage Monthly infusions, max 1000 mg/kg daily 2000 mg/kg, max 96000 mg/kg total
Age Range 50 to 80 years ≥3 years
Key Inclusion Criteria Early Alzheimer’s Disease, adequate education level Confirmed NPC1 diagnosis, neurological symptoms
Key Exclusion Criteria Other neurodegenerative diseases, severe hypothyroidism Recent liver transplant, uncontrolled seizures

FAQ

  • What is Hydroxypropylbetadex? Hydroxypropylbetadex, also known as Trappsol® Cyclo™, is a chemical compound being studied for its potential therapeutic effects in neurological disorders such as Alzheimer's Disease and Niemann-Pick Disease Type C1.
  • What conditions are being studied in these clinical trials? The clinical trials are focusing on Early Alzheimer's Disease and Niemann-Pick Disease Type C1, both of which are neurological disorders affecting brain function and overall health.
  • How is Hydroxypropylbetadex administered in these trials? In both trials, Hydroxypropylbetadex is administered as a solution for infusion, meaning it is given intravenously to patients.
  • What are the main objectives of these clinical trials? The main objectives are to assess the safety, tolerability, and potential efficacy of Hydroxypropylbetadex in patients with Early Alzheimer's Disease and Niemann-Pick Disease Type C1, as well as to determine its pharmacokinetics in some cases.
  • How long do these clinical trials last? The Alzheimer's Disease trial lasts for 24 weeks (6 months), while the Niemann-Pick Disease Type C1 trial has a longer duration of 96 weeks (approximately 2 years).

Ongoing Clinical Trials on Hydroxypropylbetadex

  • Study on the Safety and Effects of Hydroxypropylbetadex Infusions in Patients with Early Alzheimer’s Disease

    Not yet recruiting

    2 1
    Investigated drugs:
    Austria Germany

  • Study on the Safety and Effectiveness of Hydroxypropylbetadex and Miglustat for Patients with Niemann-Pick Disease Type C1

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Italy Poland Spain

Glossary

  • Hydroxypropylbetadex: A chemical compound being studied for its potential therapeutic effects in neurological disorders. It is also known as Trappsol® Cyclo™ or HP𝛽CD.
  • Early Alzheimer's Disease (EAD): The initial stage of Alzheimer's disease, characterized by mild cognitive impairment and early signs of memory loss and cognitive decline.
  • Niemann-Pick Disease Type C1 (NPC1): A rare genetic disorder that affects the body's ability to metabolize fats (cholesterol and lipids) within cells, leading to progressive neurological symptoms.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Double-blind: A study design where neither the participants nor the researchers know who is receiving the actual treatment or a placebo, to prevent bias in the results.
  • Placebo-controlled: A study that includes a group of participants who receive an inactive substance (placebo) instead of the actual treatment, used to compare the effects of the real treatment.
  • Randomized: A method of assigning participants to different treatment groups by chance, to ensure that the groups are similar and reduce bias.
  • Efficacy: The ability of a treatment to produce the desired beneficial effect under ideal conditions.
  • Standard of Care (SOC): The currently accepted and widely used treatment for a particular condition.
  • Niemann-Pick Type C Severity Scale (NPC-SS): A clinical assessment tool used to measure the severity and progression of symptoms in patients with Niemann-Pick Disease Type C.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-hydroxypropylbetadex-infusions-in-patients-with-early-alzheimers-disease/
  2. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-hydroxypropylbetadex-and-miglustat-for-patients-with-niemann-pick-disease-type-c1/